2nd Annual International Low Dose Naltrexone Awareness Week October 18 - 24, 2010

Share Article

LDN Awareness Week to Boost Worldwide Recognition of New Use of Generic Drug for Multiple Sclerosis

People with Multiple Sclerosis (MS) worldwide are preparing for the Second Annual International Awareness Week for Low Dose Naltrexone (LDN). LDN Awareness Week, which aims to educate the medical community and MS sufferers, will take place from October 18th to 24th, 2010 and coincide with a conference in the UK.

Naltrexone has been approved by the Food and Drug Administration (FDA) since 1985 for treating alcoholism and drug addiction, but in a much smaller dose it has been found a safe and effective MS treatment as well as for other autoimmune conditions, including Rheumatoid Arthritis, Fibromyalgia, Lupus and Crohn’s Disease. LDN has even been found effective in battling some cancers. Sadly, not all neurologists and doctors are prepared to prescribe LDN because it is a new, off-label use of a low cost generic drug.

Over 100,000 people currently take LDN worldwide, the majority in the United States where the drug is easily made by compounding pharmacies with a doctor’s prescription. LDN has been reported by patients and their doctors to halt MS and is most effective when taken upon early disease diagnosis - before any lasting disability has occurred. Current MS immune-suppressant therapies require painful daily or weekly injections, can have toxic side-effects, cost over $3,000 a month, and have been found to be only 30-35% effective at slowing disease progression at two years of clinical study.

LDN costs about $30 for a month’s supply, is an oral capsule taken before bedtime at night, is non-toxic, and reported by two user surveys and countless testimonials to be 70-80% effective at preventing MS disease progression. LDN could save billions of dollars in drug costs.

In the UK, where expensive MS drugs are not paid for by private health insurance, LDN is quickly being recognized by the medical community and MS charities as a MS therapy.

In the United States, the National Multiple Sclerosis Society (NMSS) has so far funded a research study at Penn State Medical on LDN’s use in mice with a MS-like disease and which confirmed the results tens of thousands of humans have already reported after taking LDN – their MS stopped getting worse.

An anticipated new LDN research study, supported by http://www.CureTogether.com and Transparency Life Sciences ( http://www.TransparencyLS.com ) will utilize a new method of open-source drug development to further prove LDN efficacy and awareness throughout the medical community.

For more information on LDN as a therapy for MS and other autoimmune conditions, please visit http://www.LDNaware.org the worldwide gateway to LDN information, resources and events.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Malcolm West (United States)

484-580-8564
Email >

Linda Elsegood (United Kingdom)

0844 41 45 295
Email >